Myasthenia Gravis, Generalized

Argenx brews up DTC push for Vyvgart Hytrulo prefilled syringe in generalized myasthenia gravis

4 weeks ago talkbio0Tagged Approved, DTC Campaign, Empowerment, Myasthenia Gravis, Generalized, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, self-administration, Syringes, United States Food and Drug Administration, Vyvgart Hytrulo

Vyvgart Hytrulo, prefilled syringe, FDA approval, self-administration, generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), DTC campaign, patient empowerment

FDA Approves Johnson & Johnson’s Imaavy: A New Treatment Option for Generalized Myasthenia Gravis

1 month ago talkbio0Tagged Approved, Autoimmune Diseases, Blocker, FCGRT gene, FcRn, Imaavy, immunoglobulin G, Myasthenia Gravis, Generalized, nipocalimab-aahu, United States Food and Drug Administration

Imaavy, nipocalimab-aahu, FcRn blocker, generalized myasthenia gravis (gMG), FDA approval, Johnson & Johnson, autoimmune disease, IgG reduction

Roche’s Phase III Trial Success with IL-6 Blocker Enspryng Tempered by Modest Outcomes

1 year ago talkbio0Tagged Blocker, disappointment, Enspryng, Expectations, interleukin-6, Myasthenia Gravis, Generalized, Phase 3 Clinical Trials, Roche (company), satralizumab

Roche, IL-6 blocker, Enspryng (satralizumab), Phase III trial, Generalized Myasthenia Gravis (gMG), Disappointment, Expectations

J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders

1 year ago talkbio0Tagged Autoimmune Diseases, Clinical Research, Erythroblastosis, Fetal, Johnson and Johnson, Myasthenia Gravis, Generalized, Nipocalimab, Sjogren's Syndrome

Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal